

Patient: [REDACTED]
 DOB: [REDACTED] Age: 28 Gender: F
 Patient Identifiers: [REDACTED]
 Visit Number (FIN): [REDACTED]


Client: [REDACTED]
 Physician: [REDACTED]

ARUP Test Code: 2008320
 Collection Date: 11/13/2018
 Received in lab: 11/14/2018
 Completion Date: 11/15/2018

Patient History *

Collection Date	Infliximab Activity (IFX) ug/mL	Neutralizing Antibody (IFX NAb) Titer	Accession Number
11/13/2018	6.29	Not Detected	18-317-401067

Infliximab Activity versus Neutralizing Antibody Titer



Cutoff values are 0.65 ug/mL for infliximab and 1:20 for antidrug antibody (NAb).

*Consecutive test results are displayed on this chart; however, this result set may be incomplete due to variations in the demographic information submitted for prior tests. If the information on this chart appears incomplete, please consult this patient's prior charts.

Interpretive Comments

Interpretive Data: This test measures the capacity of infliximab to neutralize TNF-alpha activity. Additionally, infliximab neutralizing antibodies (NAb) are titered (reporting the minimal serum dilution at which blocking of infliximab activity is no longer observed).

This test is used to evaluate secondary response failures to infliximab therapy. Secondary response failure is defined as



Patient: [REDACTED]
 ARUP Accession: 18-317-401067

Infliximab or Biosimilar Activity and Neutralizing Antibody

Patient: [REDACTED] | Date of Birth: [REDACTED] | Gender: F | Physician: [REDACTED]
 Patient Identifiers: [REDACTED] | Visit Number (FIN): [REDACTED]

loss of clinical response after initial improvement of clinical signs and symptoms. Therapeutic decision should rest on both the clinical response and the knowledge of the fate of the drug including the emergence of immunogenicity in individual patients.

Circulating infliximab levels have been shown to vary considerably between patients. These differences relate to route and frequency of administration and patient-related features such as age, gender, weight, drug metabolism, and concomitant medications such as methotrexate and other immunosuppressants.

IF Infliximab Activity is...	AND Infliximab Neutralizing Antibody Titer is...	THEN...
Not Detected	Not Detected	A higher dosage of infliximab or shortening the dosing interval may be appropriate.
Not Detected	1:20 or greater	A change to another anti-TNF-alpha drug may be appropriate.
0.65 ug/mL or greater	Not Detected	A change to another type of therapy (not targeting TNF-alpha) may be appropriate.
0.65 ug/mL or greater	1:20 or greater	Repeat testing is suggested to rule out decreasing infliximab activity and/or increasing infliximab neutralizing antibodies.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS.



Patient: [REDACTED]
 ARUP Accession: 18-317-401067
 [REDACTED]